Evolutionary Genomics, Inc.
OTC: FNAM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven Bryan Warnecke
- Employees
- 2
- Headquarters
- Castle Rock, United States
- IPO year
- 2011
- Market cap
- $1.3K
- Website
- https://www.evolgen.com
Loading FNAM…
Loading profile data…Frequently asked questions about FNAM
What does Evolutionary Genomics, Inc. (FNAM) do?
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolera...
Where does FNAM trade?
Evolutionary Genomics, Inc. (FNAM) trades on the Other OTC.
What sector is FNAM in?
Evolutionary Genomics, Inc. (FNAM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Evolutionary Genomics, Inc.?
Steven Bryan Warnecke is the chief executive officer of Evolutionary Genomics, Inc. (FNAM).
Where is Evolutionary Genomics, Inc. headquartered?
Evolutionary Genomics, Inc. is headquartered in United States.
Does FNAM pay a dividend?
Evolutionary Genomics, Inc. (FNAM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FNAM go public?
Evolutionary Genomics, Inc. (FNAM) completed its initial public offering in 2011.